Extent of exposure to umbralisib
| Extent of exposure . | FL (n = 147) . | MZL (n = 82) . | DLBCL/MCL (n = 74) . | CLL/SLL (n = 43) . | Other (n = 25) . | Total (N = 371) . |
|---|---|---|---|---|---|---|
| Duration (mo) | ||||||
| Mean ± SD | 9.8 ± 9.8 | 10.3 ± 7.0 | 4.7 ± 8.6 | 14.7 ± 13.1 | 3.9 ± 3.6 | 9.1 ± 9.7 |
| Median (min, max) | 7.3 (0.1, 75.1) | 9.4 (0.2, 24.6) | 2.3 (0.1, 65.5) | 12.5 (0.7, 55.2) | 2.3 (0.2, 14.0) | 5.9 (0.1, 75.1) |
| Duration, n (%) | ||||||
| <3 mo | 30 (20.4) | 16 (19.5) | 45 (60.8) | 6 (14.0) | 14 (56.0) | 111 (29.9) |
| 3 to <6 mo | 32 (21.8) | 16 (19.5) | 15 (20.3) | 6 (14.0) | 7 (28.0) | 76 (20.5) |
| 6 to <12 mo | 44 (29.9) | 14 (17.1) | 7 (9.5) | 9 (20.9) | 3 (12.0) | 77 (20.8) |
| 12 to <18 mo | 23 (15.6) | 19 (23.2) | 4 (5.4) | 9 (20.9) | 1 (4.0) | 56 (15.1) |
| 18 to <24 mo | 13 (8.8) | 16 (19.5) | 1 (1.4) | 6 (14.0) | 0 | 36 (9.7) |
| ≥24 mo | 5 (3.4) | 1 (1.2) | 2 (2.7) | 7 (16.3) | 0 | 15 (4.0) |
| Extent of exposure . | FL (n = 147) . | MZL (n = 82) . | DLBCL/MCL (n = 74) . | CLL/SLL (n = 43) . | Other (n = 25) . | Total (N = 371) . |
|---|---|---|---|---|---|---|
| Duration (mo) | ||||||
| Mean ± SD | 9.8 ± 9.8 | 10.3 ± 7.0 | 4.7 ± 8.6 | 14.7 ± 13.1 | 3.9 ± 3.6 | 9.1 ± 9.7 |
| Median (min, max) | 7.3 (0.1, 75.1) | 9.4 (0.2, 24.6) | 2.3 (0.1, 65.5) | 12.5 (0.7, 55.2) | 2.3 (0.2, 14.0) | 5.9 (0.1, 75.1) |
| Duration, n (%) | ||||||
| <3 mo | 30 (20.4) | 16 (19.5) | 45 (60.8) | 6 (14.0) | 14 (56.0) | 111 (29.9) |
| 3 to <6 mo | 32 (21.8) | 16 (19.5) | 15 (20.3) | 6 (14.0) | 7 (28.0) | 76 (20.5) |
| 6 to <12 mo | 44 (29.9) | 14 (17.1) | 7 (9.5) | 9 (20.9) | 3 (12.0) | 77 (20.8) |
| 12 to <18 mo | 23 (15.6) | 19 (23.2) | 4 (5.4) | 9 (20.9) | 1 (4.0) | 56 (15.1) |
| 18 to <24 mo | 13 (8.8) | 16 (19.5) | 1 (1.4) | 6 (14.0) | 0 | 36 (9.7) |
| ≥24 mo | 5 (3.4) | 1 (1.2) | 2 (2.7) | 7 (16.3) | 0 | 15 (4.0) |
Duration of exposure (mo) = (date of last dose – date of first dose + 1)/30.4375.
MCL, mantle cell lymphoma; SD, standard deviation.